Cell-based therapies set to become major players in the osteoarthritis market
The development of disease-modifying osteoarthritis drugs is thought to be the greatest current unmet need in osteoarthritis.
By
Immunology
Latest in
Immunology
Pfizer and CytoReason extend partnership for AI-driven drug discovery
The partnership would be worth up to $110m over the next five years.
Exploring opportunity and unmet needs in busy ulcerative colitis space
Developing drugs that avoid systemic immune modulation could be an area of growth in the ulcerative colitis therapeutics market.
By
US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis
The approval is based on data from the Phase III POETYK PSO-1 and POETYK PSO-2 trials.
Rare Disease Spotlight-oncology therapies dominate the orphan drug landscape
The second edition of the Rare Disease Spotlight series investigates the trends in orphan drug designations across therapy areas over…
By
Sonoma signs deal to set up manufacturing centre for cell therapies
A cGMP-compliant production facility will be housed at the centre for manufacturing cell products at scale.
Q32 Bio and Horizon partner to develop autoimmune disease treatment
Q32 is entitled to get $55m as initial consideration and staged development funding during the option period.
Amgen to acquire biopharma firm ChemoCentryx for $3.7bn
The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.